

Biosensors for Whole-Cell Bacterial Detection

Asif Ahmed, Jo V. Rushworth,* Natalie A. Hirst, Paul A. Millner

School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

SUMMARY	631
INTRODUCTION	631
BIOSENSORS FOR DETECTION OF BACTERIA	633
BIOSENSORS FOR WHOLE BACTERIAL CELL DETECTION	633
Optical Biosensors	634
Mechanical Biosensors	636
Electrochemical Biosensors	637
Potentiometric sensors	637
Amperometric sensors	637
Impedimetric sensors	638
CONCLUSIONS AND FUTURE PERSPECTIVES	641
ACKNOWLEDGMENTS	642
REFERENCES	642
AUTHOR BIOS	645

SUMMARY

Bacterial pathogens are important targets for detection and identification in medicine, food safety, public health, and security. Bacterial infection is a common cause of morbidity and mortality worldwide. In spite of the availability of antibiotics, these infections are often misdiagnosed or there is an unacceptable delay in diagnosis. Current methods of bacterial detection rely upon laboratory-based techniques such as cell culture, microscopic analysis, and biochemical assays. These procedures are time-consuming and costly and require specialist equipment and trained users. Portable stand-alone biosensors can facilitate rapid detection and diagnosis at the point of care. Biosensors will be particularly useful where a clear diagnosis informs treatment, in critical illness (e.g., meningitis) or to prevent further disease spread (e.g., in case of food-borne pathogens or sexually transmitted diseases). Detection of bacteria is also becoming increasingly important in anti-bioterrorism measures (e.g., anthrax detection). In this review, we discuss recent progress in the use of biosensors for the detection of whole bacterial cells for sensitive and earlier identification of bacteria without the need for sample processing. There is a particular focus on electrochemical biosensors, especially impedance-based systems, as these present key advantages in terms of ease of miniaturization, lack of reagents, sensitivity, and low cost.

INTRODUCTION

Bacterial pathogens are important targets for detection and identification in various fields, including medicine, food safety, public health, and security. Infectious diseases are among the leading causes of morbidity and mortality worldwide, causing millions of deaths and hospitalizations each year. The World Health Organization (WHO) identified infectious and parasitic diseases collectively as the second-highest cause of death worldwide in 2004, with lower respiratory tract infections (third), diarrheal diseases (fifth), and tuberculosis (seventh) being among the top 10 leading causes of death in 2011 (http://www.who.int/gho/mortality_burden_disease/causes_death/2000_2011/en/index.html). These types of infectious or communicable diseases are

most problematic in low-income countries, such as countries in Africa, where medical facilities and methods of diagnosis and treatment are lacking. Food-borne pathogens also pose a serious health risk in higher-income countries, including the United States, where food-borne bacteria cause an estimated 76 million illnesses, 300,000 hospitalizations, and 5,000 deaths each year (1, 2). *Escherichia coli* O157:H7, salmonellae, *Campylobacter jejuni*, and *Listeria monocytogenes* are the leading causes of bacterial food- and waterborne illnesses.

Table 1 summarizes the burden of disease, annual cases, and mortality of the most common bacterial diseases worldwide. Despite the widespread, global availability of antibiotics, the primary cause of mortality or serious illness is delayed or inaccurate diagnosis of the bacterial infection. This underlines the urgent need for more specific and rapid analytical tests that can be employed at the point of care.

Conventional, laboratory-based methods of bacterial detection and identification typically have long processing times, can lack sensitivity and specificity, and require specialized equipment and trained users and are therefore costly and not available in all countries (3). Typically, specimens (e.g., blood, saliva, urine, or food sample) are sent for microbiological analysis using various techniques, namely, microscopy and cell culture, biochemical assays, immunological tests, or genetic analysis. Microscopy involves staining bacteria and observing their morphology and staining pattern, and it is relatively quick but not specific, whereas culturing bacteria on selective media under particular growth conditions can take up to several days. Furthermore, not all bac-

Address correspondence to Asif Ahmed, bsaa@leeds.ac.uk.

* Present address: Jo V. Rushworth, School of Allied Health Sciences, De Montfort University, Leicester, United Kingdom.

A.A. and J.V.R. contributed equally to this article and are co-first authors.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.

doi:10.1128/CMR.00120-13

TABLE 1 Common global diseases caused by bacterial infection and their burdens of disease and mortality^a

Disease(s)	Causative bacterial agent(s)	Burden of disease (DALY), millions	Annual deaths, millions	Annual cases, millions	Conventional methods of diagnosis	Diagnosis time critical?	Spread prevention critical?	Reference(s)
Lower respiratory tract infections (e.g., pneumonia)	<i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i>	94.5	4.2	430	Physical examination, chest X-ray, sputum and blood cultures, PCR	No	No	11
Diarrheal diseases	Shigellae, <i>Campylobacter</i> , salmonellae, <i>Escherichia coli</i> O157:H7	72.8	2.1	4,620	Microbiology (culture on Gram-negative-selective media), PCR, ELISA, particle agglutination assay	Can be	Yes	12, 13
TB	<i>Mycobacterium tuberculosis</i>	34.2	1.5	7.8	Chest X-ray, blood test, Mantoux TST, sputum smear and culture, staining and microscopy	No	Yes	14
Meningitis	<i>Neisseria meningitidis</i> , <i>Streptococcus pneumoniae</i> , <i>Escherichia coli</i>	11.4	0.34	0.7	Lumbar puncture, blood cultures, PCR	Yes	No	15
Sexually transmitted infections (excluding HIV)	<i>Treponema pallidum</i> (syphilis), <i>Chlamydia trachomatis</i> (chlamydia), <i>Neisseria gonorrhoeae</i> (gonorrhoea)	10.4	0.13	222	Urethral/vaginal swab and culture; Gram staining and microscopy; immunoassay, particle agglutination assay	No	Yes	16, 17

^a Abbreviations: DALY, disability-adjusted life years (i.e., number of years lost due to disease); ELISA, enzyme-linked immunosorbent assay; TB, tuberculosis; TST, tuberculin skin test; HIV, human immunodeficiency virus.

teria can be cultured in the laboratory. Biochemical assays include detection of particular enzymes that are bacterium specific. Immunological tests include enzyme-linked immunosorbent assays (ELISAs) and agglutination assays and are usually employed to detect particular surface epitopes. These processes are all time-consuming and costly due to the specialist technical staff and equipment required. The advent of molecular techniques such as genetic analysis has enabled more rapid identification of bacterial strains (4). PCR, an extremely sensitive technique which allows for the identification of bacteria based on their genetic material, does not require a bacterial culture step due to the small sample size required (5). PCRs need preselected genetic probes to be used to correctly pair with the target bacterial sequence. Wrong pairing may result in false-positive results, and genetically mutated strains might escape the correct probe matching. However, this is still a lengthy and expensive procedure which can take several days. Real-time PCR analysis can be completed faster, within several hours, but still requires specialist equipment and reagents (6). Critically, all of these techniques take time, require sample preparation and particular reagents and equipment, and are therefore costly. There is, therefore, an urgent demand for more rapid, cost-effective, and sensitive tests which can identify whole bacteria in the field or at the point of care, bypassing multistep processing and purification.

Particularly for clinical diagnosis and treatment, rapid identification of bacteria can be critical to the clinical outcome. For example, in the case of bacterial meningitis, there is a clear negative correlation between diagnosis time and patient survival (7) or serious and disabling sequelae such as deafness, blindness, and loss of limbs. The present diagnostic methods of lumbar puncture (which itself is hazardous) alongside neuroimaging and bacterial staining are time-consuming and delay critical administration of antibiotic therapy. A biosensor test that could detect and identify the cause of meningitis within minutes is required urgently.

For other bacterial infections, diagnostic time is less critical to clinical outcome but can be extremely important in decreasing the spread of infection, for instance, in the case of sexually transmitted infections (STIs) such as syphilis, gonorrhoea, and chlamydia, which can be asymptomatic. Often, potentially infected people who attend a clinic do not return for results and treatment, particularly in low-income countries where a clinic is usually a long walk from home (8). In this instance, a point-of-care test that could provide a “while-you-wait” diagnosis would allow for immediate commencement of antibiotic therapy and the prevention of disease spread. In some clinical settings such as accident and emergency departments, screening of antibiotic-resistant “superbugs,” namely, methicillin-resistant *Staphylococcus aureus* (MRSA) and *Clostridium difficile*, may be obligatory prior to admission. Point-of-care screening would be enormously useful in providing immediate results which allow for barrier nursing and appropriate precautionary measures to be put in place to decrease the risk of infection to others.

In the case of food-borne infections arising from contaminated food or beverages, rapid and correct identification of the contaminated items, followed by their removal from sale, is desirable for the prevention of further illnesses (2). In the worst reported incident of food poisoning in the United States, consumption of soft cheese contaminated with *Listeria monocytogenes* resulted in 47 deaths over a period of approximately 6 months until the source was identified (9).




FIG 1 Publications on biosensors for the field in general compared with the specific detection of whole bacteria. (A) Different detection methods being used in biosensing platforms, including published literature found in ISI Web of Science using the search terms “biosensor” and “used technique” from 1983 to 2013. (B) Different techniques used for the detection of whole bacteria. The size of the circle or bacterium is proportional to the number of publications associated with that technique.

Following bioterrorism attacks in recent years, there is also the increasing need for field-based tests for biological warfare agents (BWAs), such as those causing anthrax (*Bacillus anthracis*) and plague (*Yersinia pestis*) (10). Two types of sensors are required here, one to provide an early-warning system for screening of potentially contaminated items and another to test potentially infected individuals for microorganisms.

BIOSENSORS FOR DETECTION OF BACTERIA

Biosensors offer a rapid and cost-effective method of bacterial detection which can be performed at the point of care without the need for a specialist user (18). This “lab-on-a-chip” method of patient diagnosis and monitoring provides a more rapid diagnosis which allows for faster and more effective therapeutic intervention, thereby preventing full-blown infection and mortality and also decreasing the spread of disease.

Biosensors essentially comprise a biorecognition element that is coupled to some form of transducer, which converts specific analyte binding to bioreceptors into a measurable or detectable readout. Biosensors can be categorized in different ways, either according to the method of signal transduction (i.e., optical, mechanical, or electrical) or by the type of bioreceptor employed (i.e., catalytic [enzyme] or affinity based [antibody, aptamer, lectin, bacteriophage, etc.]). Generally, affinity-based sensors are preferred over enzymatic biosensors for the detection of microorganisms, due to their enhanced selectivity and specificity and lack of extra reagents required. The biosensor field is expanding rapidly, with amperometric and optical techniques being the most commonly used over the last 30 years, whereas the use of more recent methods such as impedance and fiber optics is now increasing (Fig. 1A).

Biosensors have been developed for many different analytes, which range in size from individual ions and small molecules to nucleic acids and proteins up to whole viruses and bacteria (18). In the case of bacterial sensing, two classes of biosensors have been developed: (i) those which require sample processing to achieve

bacterial disruption or lysis in order to liberate the target bacterial component and (ii) processing-free systems which target whole bacteria. In the first category, biosensors detect bacterial components such as DNA (19, 20), RNA (e.g., rRNA) (21, 22), intracellular proteins such as enzymes (23), and secreted exotoxins (24). The major disadvantage of these systems is the requirement for sample processing and extra reagents, which increases the time and cost of these tests. Therefore, biosensors for the direct, reagentless detection of whole bacteria are much more desirable for rapid, cost-effective testing at the point of care. This is particularly useful because the infectious dose of bacteria for many human pathogens is very low; for *E. coli* O157:H7 this has been reported to be as low as only 10 cells per gram of food or environmental sample (25).

BIOSENSORS FOR WHOLE BACTERIAL CELL DETECTION

Significant research efforts are now focused upon the detection of whole bacteria (26, 27) (Fig. 1B). It is observed that in terms of whole bacteria, impedimetric and optical methods are most commonly used. The development of biosensors for whole microorganisms is challenging because it requires detection of analytes that are much larger (micrometer scale) than typical molecular analytes such as proteins (nanometer scale), and bacteria display many surface epitopes that can lead to nonspecific interactions with the sensor surface.

Bacteria are typically between 0.5 and 5 μm in size, displaying different morphologies, including spherical cocci, rod-shaped bacilli, and spiral-shaped spirilla or spirochetes, among others. Unlike eukaryotic cells, most bacteria are encapsulated by a cell wall which is present on the outside of the cytoplasmic membrane (Fig. 2). The cell wall comprises mainly peptidoglycan, a negatively charged polymer matrix comprising of cross-linked chains of amino sugars, namely, *N*-acetylglucosamine and *N*-acetylmuramic acid. Bacteria can be classified as either Gram positive or Gram negative depending upon the architecture and thickness of the cell wall. Gram-positive bacteria retain the violet Gram stain




FIG 2 Bacterial architecture and targets for biosensing. The cell wall of Gram-positive bacteria comprises a thick layer of peptidoglycan, which also contains lipids and other protein components, surrounding a lipid membrane. In contrast, Gram-negative bacteria possess a much thinner peptidoglycan layer sandwiched in between two cell membranes. The outer membrane contains proteins, such as porins, as well as lipopolysaccharides (LPS), also known as endotoxin. The inner membranes of both types of bacteria contain various proteins. Both types of bacteria may have flagella. Intracellular targets for biosensing include proteins, DNA, and RNA.

due to their thick peptidoglycan layer on the outside of the cell membrane. In contrast, Gram-negative bacteria do not take up the stain, as their thinner peptidoglycan layer is sandwiched between two cell membranes. The outer lipid membrane of Gram-negative bacteria also contains lipopolysaccharides (LPS), which act as endotoxins and elicit a strong immune response in humans, as well as various proteins, including porins. The thick peptidoglycan wall surrounding Gram-positive bacteria contains extra components such as lipids, surface proteins, and glycoproteins. Pathogenic Gram-negative bacteria include *Escherichia coli*, *Salmonella*, *Shigella*, *Legionella*, *Haemophilis influenzae*, *Neisseria gonorrhoeae*, and *Neisseria meningitidis*. Examples of pathogenic Gram-positive bacteria include *Streptococcus*, *Staphylococcus*, *Bacillus*, and *Clostridium*.

A variety of surface antigens presented on the cell envelopes of whole bacteria, including proteins, glycoproteins, lipopolysaccharides, and peptidoglycan, can act as targets for biorecognition. Certain bioreceptors have been developed to target a specific one of these moieties; for example, lectins, a type of carbohydrate binding protein, can be employed as bioreceptors for specific cell envelope sugars (28, 29). Bacteriophages, viruses which bind to specific bacterial receptor proteins in order to infect the host cells, have also been employed for bacterial detection (30, 31). Polyclonal antibodies raised against specific bacterial strains are the most commonly used bioreceptors for whole bacterial cell detection, where the binding targets on the cell envelope are usually unknown. To increase the specificity and sensitivity of the sensor, isolated surface epitopes can be used to produce monoclonal antibodies (32, 33).

The ideal parameters for whole bacterial sensors are almost

identical to the requirements for a general biosensor. Depending on the site of use, for example, stand-alone personal use at home or clinical setup, regular use in a laboratory setup, or remote regular use off site (polluted water or wastewater site), the configuration might vary, but the key properties for commercial biosensors to detect bacteria are constant. They should be inexpensive, small, easy to operate and label free, with little or no sample preparation. Important key features for an ideal bacterial biosensor are presented in Table 2.

Optical Biosensors

Optical biosensors exploit analyte binding-induced changes in the optical properties of the sensor surface, which are then transduced to a detector. Optical biosensors are often divided into two categories, fluorescence based or label free (34). Examples of both are presented in Table 3. The simplest optical biosensors function by measuring a change in fluorescence or, less commonly, in absorbance or luminescence of the biosensor surface upon analyte recognition. These technologies have evolved from traditional sandwich immunoassays, where the biorecognition element comprises immobilized antibodies which allow for specific analyte detection. A secondary reagent, such as a fluorescently labeled antibody, then binds to the captured analyte on the sensor surface. This generates an optical signal, the strength of which is proportional to specific analyte binding. To convert these assays from a laboratory-based 96-well plate format to a smaller, more portable biosensor system, optical fibers have been employed for the detection of whole bacterial cells (35, 36). Fiber optic biosensors (FOB) typically comprise a source of light which passes through optical fibers containing immobilized bioreceptors to a photon detector. Analyte binding and subsequent addition of an appropriate labeling reagent give rise to a change in signal at the detector. Fluorescence-based biosensors can provide excellent sensitivity; for instance, Mouffouk and colleagues used a fluorescent dye-loaded micelle approach to detect 15 cells/ml of *E. coli* (37). However, the major disadvantage of using fluorescence-based optical biosensors is the requirement for sample labeling with fluorescent reagents, which adds time and cost to the procedure.

Surface plasmon resonance (SPR) is a label-free method of op-

TABLE 2 Requirements for an ideal bacterial biosensor

Parameter	Value or quality
Sensitivity	Less than 10^3 CFU/ml
Specificity	Can distinguish different serotypes of bacteria (e.g., can distinguish <i>E. coli</i> Nissle 1917 from <i>E. coli</i> O157:H7), minimal background, must operate in complex matrices (e.g., clinical samples such as sputum and blood, food, and beverage samples)
Speed	5–10 min for a single test
Size	Compact, portable device that can operate at the site of interest
Sample processing	Label free with minimal sample processing
Stability	Biorecognition element must be stable at the high temperatures experienced in some countries (e.g., up to 45°C) for several months to allow for good shelf life
Skill of operator	No specialist training needed to use the assay, can be used by patients

TABLE 3 Examples of optical biosensors for detection of whole bacterial cells^a

Target analyte(s)	Transducer signal	Sensor assembly	Bioreceptor(s)	LOD	Analyte(s)	Reference(s)
Various, e.g., <i>Salmonella</i> Typhimurium, <i>Escherichia coli</i> O157:H7, <i>Shigella dysenteriae</i> , <i>Campylobacter jejuni</i>	Fluorescence	NRL array sensor (fluorescence-based affinity assay)	Antibody, ganglioside receptors, oligosaccharides	2×10^3 – 8×10^4 CFU/ml	Food or environmental samples	35
<i>Salmonella enterica</i> , <i>Listeria monocytogenes</i> , <i>Escherichia coli</i> O157:H7	Fluorescence	Antibodies linked via biotin/avidin to optical fibers	Polyclonal antibody for capture, fluorescent monoclonal antibody or aptamer against surface protein InlA as reporter	10^3 CFU/ml	Artificially contaminated meat samples	50, 51
<i>Escherichia coli</i>	Fluorescence	Bioconjugated magnetic beads for capture, fluorescent polymeric micelles for reporting	Polyclonal anti- <i>E. coli</i> antibodies	15 cells/ml	Bacteria in buffer	37
<i>Escherichia coli</i>	Thin-film optical interference spectroscopy	Antibody-functionalized nanostructured oxidized porous silicon (PSiO ₂)	Anti- <i>E. coli</i> polyclonal antibody	10^4 cells/ml	Bacteria in buffer	52
<i>Salmonella</i> Typhimurium	Light scattering	Immunoagglutination assay using anti- <i>Salmonella</i> -conjugated polystyrene microparticles	Anti- <i>Salmonella</i> polyclonal antibody	10 CFU/ml	Liquid from processed raw chicken	53
<i>Shewanella oneidensis</i>	SERS	Silver nanoparticles sandwiched by analyte binding on optical fiber tip	NA	10^6 cells/ml	Bacteria in buffer	54
<i>Escherichia coli</i> , <i>Staphylococcus aureus</i> , <i>Bacillus subtilis</i>	SPR	Lectin-functionalized anisotropic silver nanoparticles	Potato lectin	1.5×10^4 CFU/ml	Bacteria in serum-spiked buffer	42
<i>Escherichia coli</i> O157:H7	Long-range SPR	Antibodies on SAM-gold surface/ antibody-functionalized magnetic nanoparticles	Anti- <i>E. coli</i> antibody	50 CFU/ml	Bacteria in buffer	39
<i>Escherichia coli</i>	SPR	Bacteriophage covalently bound to SiO ₂ optical fibers	T4 bacteriophage	10^3 CFU/ml	Bacteria in buffer	41

^a Abbreviations: SERS, surface-enhanced Raman scattering; SPR, surface plasmon resonance; NA, not applicable.

TABLE 4 Examples of mechanical biosensors for detection of whole bacterial cells^a

Target analyte	Transducer signal	Sensor assembly	Bioreceptor	LOD	Analyte	Reference
<i>E. coli</i> O157:H7	QCM	Antibody for capture and antibody-functionalized nanoparticles for signal enhancement	Anti- <i>E. coli</i> antibody	10 ⁶ cells/ml	Bacteria in buffer	56
<i>Bacillus anthracis</i>	QCM	Protein A/antibody-functionalized SAM on gold	Anti- <i>B. anthracis</i> antibody	1 × 10 ³ CFU or spores/ml	Vegetative cells and spores	60
<i>Salmonella</i> Typhimurium	QCM	Immunosensor sandwich assay using gold nanoparticles for signal amplification	Anti- <i>Salmonella</i> Typhimurium antibody	10 CFU/ml	Bacteria spiked into meat samples	58
<i>E. coli</i> O157:H7	PEMC	Antibody-functionalized cantilever	Anti- <i>E. coli</i> antibody	1 cell/ml	Bacteria in buffer	68
<i>Vibrio cholerae</i> O1	Microcantilever/DFM	Antibody-functionalized SAM on gold	Anti- <i>V. cholerae</i> antibody (monoclonal)	1 × 10 ³ CFU/ml	Bacteria in buffer	66
<i>Listeria monocytogenes</i>	PEMC	Protein G/antibody with postcapture antibody binding for signal amplification	Anti- <i>L. monocytogenes</i> antibody for capture, secondary antibody for signal amplification	1 × 10 ² cells/ml	Bacteria in milk	69

^a Abbreviations: QCM, quartz crystal microbalance; PEMC, piezoelectric-excited millimeter-size cantilever; DFM, dynamic force microscopy.

tical sensing which has been employed for the detection of a range of analytes since the first commercially available device was launched by Biacore (GE Healthcare) in 1990 (38). SPR systems comprise a source of plane-polarized light which then passes through a glass prism, the bottom of which contacts the bioreceptor-functionalized transducer surface, which is typically a thin film of gold. Analyte binding to the transducer surface changes its refractive index, which in turn alters the angle of light exiting the prism (the SPR angle). Various SPR-based biosensors have been developed for the detection of whole bacterial cells using a variety of bioreceptors, including antibodies (39, 40), bacteriophages (31, 41), and lectins (29, 42).

The detection of whole bacteria using SPR generally yields low sensitivity compared to that using other techniques, due to factors including limited penetration of bacteria by the electromagnetic field and the similarity in refractive index between the bacterial cytoplasm and the aqueous medium (43). Localized surface plasmon resonance (LSPR), a process where noble metal nanoparticles are used to enhance the sensitivity of the system, has been used recently (44). Recent strategies to improve the sensitivity of SPR-based bacterial sensors include transducer surface modifications (45), using nanorods for multiple detection (46), sandwich-type assays including nanoparticles for analyte capture to boost the signal (42), and the use of modified SPR systems, such as long-range SPR, which are better suited to large analytes (39). For the detection of whole bacteria, LSPR is reported to be less sensitive (47) and sometimes limited by unclear sample when a biological matrix is used (48). Surface-enhanced Raman scattering (SERS) is another modification where the Raman spectrum is enhanced manifold and has been used in combination with other techniques to detect bacterial cells even in blood medium (49). However, SPR-based systems in general still remain large, expensive pieces of equipment which have not yet been adapted for point-of-care diagnostics. Coin-size Spreeta SPR chips (Texas Instruments Inc.) have recently permitted the development of a miniaturized SPR-based biosensor, although this still required a microfluidic system and is therefore confined to the laboratory.

Furthermore, interference from biological samples means that an SPR-based biosensor that operates successfully in physiological media has yet to be developed.

Mechanical Biosensors

Mechanical biosensors confer several advantages for use at the point of care; they can provide high sensitivity and quick processing times without the need for sample processing or extra reagents (55). The two main categories of mechanical biosensors are based on quartz crystal microbalance (QCM) or cantilever technology (Table 4).

QCM sensors are label-free piezoelectric biosensors which detect the resonance frequency change that results from increased mass on the sensor surface due to analyte binding. QCM sensors have been developed for the detection of whole bacterial cells, including *Escherichia coli* (56, 57), *Salmonella enterica* serovar Typhimurium (58), *Campylobacter jejuni* (59) and *Bacillus anthracis* (60). The development of sandwich-type assays which employ nanoparticles for signal amplification has allowed for the detection of very few bacterial cells, down to 10 CFU/ml in some cases (58).

Microcantilever sensor technology is an emerging label-free technique that offers very high sensitivity, fast response times, and ease of miniaturization for the development of point-of-care sensors (61, 62). Cantilever sensors typically comprise a bioreceptor-functionalized microcantilever which oscillates at a particular resonant frequency. The resonant frequency of the cantilever changes due to induced mechanical bending upon an increase in mass on the sensor surface. Microcantilever sensors have been developed for the detection of various whole bacteria, including *Escherichia coli* O157:H7 (63, 64), *Salmonella* Typhimurium (65), *Vibrio cholerae* (66), and the biowarfare agent *Francisella tularensis* (67). The recently developed piezoelectric-excited millimeter-size cantilevers (PEMC) using antibodies as bioreceptors have been able to detect as few as one *E. coli* cell in buffer (68) and one hundred *Listeria monocytogenes* cells in milk (69). A major disadvantage of cantilever-based systems is that they are often limited

TABLE 5 Examples of potentiometric and amperometric electrochemical biosensors for detection of whole bacterial cells^a

Biosensor type	Bacterium	Transducer	Technique	Bioreceptor	LOD	Comment	Reference
Potentiometric	Sulfate-reducing bacteria <i>Staphylococcus aureus</i>	Glassy carbon electrode Single-walled carbon nanotubes	Potentiometric stripping analysis EMF	None Aptamer	2.3×10^{-2} – 2.3×10^7 CFU/ml 8×10^2 CFU/ml	Need bacterial processing Bacterium-spiked pig skin	74 75
Amperometric	<i>E. coli</i>	Photolithographic gold	Immunomagnetic/amperometric in flow cells	Antibody	55 cells/ml in PBS, 100 cells/ml in milk	No contact of biocomponent with sensor Cells not intact after analysis	76
	<i>E. coli</i> K-12	Screen-printed carbon electrodes	Phage-induced release and subsequent quantitation of bacterial intracellular enzyme	Bacteriophage	1 CFU/100 ml	Cells not intact after analysis	77
	Heat-killed <i>E. coli</i>	SCE	Amperometric detection of secondary antibody with GOD	Biotinyl antibody	3×10^1 – 3.2×10^6 CFU/ml, down to 15 CFU/ml	Labeling needed but tested in synthetic stool	78
	<i>Staphylococcus aureus</i>	Dropsens screen-printed gold electrodes	HRP H ₂ O ₂ -mediated immunosensor	Antibody	1 CFU/ml of raw milk	Indirect, label needed	79

^a Abbreviations: SCE, saturated calomel electrode; GOD, glucose oxidase; EMF, electron motive force; HRP, horseradish peroxidase.

by the need to operate in air as opposed to in physiological media, and there is a dearth of reports in which cantilever-based sensors have been tested in relevant matrices such as food or patient samples (70).

Electrochemical Biosensors

Electrochemical biosensors comprise potentiometric, amperometric, and impedimetric sensing techniques, with amperometric sensors the first type of biosensors to be described, in 1953 (71). Electrochemical biosensors have subsequently become the most developed group with greatest commercial success, largely due to amperometric glucose detection in diabetic monitoring (72). Their key advantages are low cost, point-of-care testing, and miniaturization capacity (73).

Potentiometric sensors. Potentiometric biosensing uses ion-selective electrodes to measure the potential of a solution based on specific interactions with ions in the solution. This method measures the change in potential that occurs upon analyte recognition at the working electrode. Although potentiometry is widely used in the biosensor field, examples of potentiometric biosensors for the detection of whole bacterial cells are few. Compared to other methods such as impedance, potentiometry cannot provide specific and sensitive signals for large analytes such as bacteria. However, some innovative applications of potentiometry can provide reasonable limits of detection (LODs) (Table 5), as discussed briefly here.

Potential stripping analysis (PSA) is a chrono-potentiometric method where the stripping time of a deposited compound can be measured at a set stripping potential. Marine pathogenic bacteria (sulfate-reducing bacteria [SRB]) have been detected using this method, where bacterial samples were preincubated with lead and nitric acid to produce sulfide (74). This sulfide can be detected by PSA, as with increasing concentration of bacterial sample, a longer time is needed for stripping. Although the detection range of PSA is good, the preincubation steps are not suitable for rapid and on-site detection methods.

Staphylococcus aureus, a common skin commensal, has been detected using label-free potentiometric detection (75). Electromotive force (EMF) was measured in a single-wall carbon nanotube-based aptamer system. The real-time EMF bacterial binding generated a linear signal with increasing concentration, with a detection limit of 8×10^2 cells/ml when the aptamer was covalently bound to the nanotubes.

Amperometric sensors. Following the introduction of enzyme-based amperometric sensing of glucose 40 years ago (80), this technique has been applied commonly to a wide range of analytes, including whole bacteria (Table 5). Amperometric biosensors are based on direct measurement of the current generated by the oxidation or reduction of species produced in response to analyte-bioreceptor interaction. The bioreceptor component is commonly an enzyme such as glucose oxidase, which is used in all medical glucose monitors (81). The current generated is directly proportional to the analyte concentration and therefore is easily determined (72). Indeed, key advantages of amperometric biosensors are their relative simplicity and ease of miniaturization. They also generally confer excellent sensitivity. Limitations include low specificity depending on the applied potential, which if high may allow other redox-active species to interfere with the signal and lead to inaccuracies in results (82). This is of particular relevance in biological media, which may contain a wealth of potential in-

terferents. Crucially, amperometric biosensors also require the analyte of interest to be a substrate for an enzymatic reaction, which is a fundamental limitation in attempting to broaden the use of this type of biosensor. Therefore, although in the field of biosensing amperometry is the most common detection method, in the case of whole-cell bacterial sensing this is not as widely used.

A novel method of differentiating hemolytic from nonhemolytic bacteria within a mixed population using liposome-trapped electron mediators with amperometric detection was reported (83). Hemolytic bacteria can disrupt liposomes, thus releasing electron mediators in the medium, which can be detected with the increase in current, whereas control bacteria lack this ability, with no current change in the system. However, this system yielded a low detection limit, ranging from 5×10^5 to 2×10^7 CFU/ml.

The amperometric detection of *E. coli* in a microfluidic system coupled with immunomagnetic capture has been reported (76). In brief, the specific antibody-conjugated magnetic particles were suspended on top of a gold electrode surface inside a flow cell by magnetic force. The bacterial sample was pumped into the cell, followed by the addition of a horseradish peroxidase (HRP)-conjugated antibody label which binds in a sandwich fashion. HRP catalyzes H_2O_2 in the presence of the electron mediator hydroquinone and produces measurable current. The amperometric detection limit of this sensor was 55 cells/ml of *E. coli* in phosphate-buffered saline (PBS) and 100 cells/ml in milk. The use of hanging bioreceptors leaves the gold electrode surface clean, limiting electrode fouling. However, the use of labeling reagents and a microfluidic system limits its point-of-care use.

Bacteriophages, or phages, are viruses with the ability to infect and lyse specific bacterial strains. Amperometric quantification of coliform *E. coli* K-12 was achieved by the phage-mediated release of the intracellular bacterial enzyme β -D-galactosidase from bacterial cells upon screen-printed carbon electrodes (77). Phage-mediated cell lysis increases specificity while boosting sensitivity through enzyme release to achieve a higher amperometric signal. The sensor was able to detect 1 CFU/100 ml of sample but had the disadvantage of the need for preincubation of bacterial cells with enzyme enhancer and phage.

A complex amperometric sensor was constructed to detect heat-killed *E. coli* strains spiked into synthetic stool samples (78). First, a biocompatible nanolayer of fullerene (C60), ferrocene (Fc), and thiolated chitosan (CHI-SH) composite was deposited on top of glassy carbon electrodes, followed by conjugation of Au-SiO₂-streptavidin-biotinyl primary antibodies. Target bacteria were detected and quantified by sandwich detection using secondary antibodies tagged with Pt nanochains and glucose oxidase. Current change was measured in the presence of glucose. Although the detection limit was low (15 CFU/ml) and the system functioned in synthetic stool samples, multistep sensor construction and the use of several labels make the system complicated.

Indirect amperometric detection of *Staphylococcus aureus* was achieved using a competitive magnetic immunoassay with a detection limit of 1 CFU/ml (79). Commercial screen-printed gold electrodes were used to construct the immunosensor. Antibodies against protein A were immobilized on magnetic beads upon the sensor surface. *S. aureus*, which displays protein A on the cell surface, was captured by the antibodies and was quantitatively detected by adding HRP-protein A as a competitor. However, the system requires labels and the signal enhancer tetrathiafulvaline, again negating its point-of-care usefulness.




FIG 3 Structure and electrochemical function of impedimetric biosensors for bacterial detection. (A) Layer-by-layer sensor construction typically comprises an electrode surface functionalized (e.g., using a polymer or self-assembled monolayer) to allow for attachment of bioreceptors, including antibodies, half-antibodies, artificial binding proteins, nucleic acid aptamers, and bacteriophages. Most impedance-based systems utilize electron mediators, e.g., ferri/ferrocyanide [$Fe(CN)_6^{3-/4-}$] to monitor charge transfer resistance. The diagram is not to scale. The Randles circuit illustrates the components of the system: double-layer capacitance (C_{dl}), charge transfer resistance (R_{ct}), solution resistance (R_s), and Warburg impedance (W) (W is observed only in some systems at low frequency). (B) Nyquist plot showing the features of the Randles circuit. (C) Impedance changes resulting from analyte-surface interactions are proportional to analyte concentration.

Impedimetric sensors. Impedimetric biosensors are a very promising choice for the detection of whole bacteria, being label free, less costly than other systems, highly sensitive, and not affected by the presence of other analytes or colored compounds in the sample matrix. Crucially, impedimetric systems are easy to miniaturize, which facilitates their translation to point-of-care systems.

Since the late 19th century, after Oliver Heaviside coined the term “impedance,” electrochemical impedance spectroscopy (EIS) has been employed to characterize different biological systems (18). Impedimetric biosensors function by analyte-bioreceptor interaction causing a change in capacitance and electron transfer resistance across a working electrode surface (Fig. 3). As analyte binding increases with higher analyte concentration, the impedance across the electrode surface changes and is detected at a transducer. The impedance may be seen to increase or decrease depending on the analyte (84). Bioreceptors are commonly antibodies, although they may be other molecules capable of detecting a wide range of analytes from proteins up to whole bacteria and viruses (85, 86). A main advantage of impedance biosensors is the unrestricted measurement of the molecule of interest, with no requirements for the analyte to be an enzymatic substrate or for formation of electroactive species as in amperometric sensing. Currently there are no impedance biosensors that have had widespread commercial success, although this technology is increasing in use rapidly, with clear evidence of a growing number of publications within this field. Disadvantages of impedance biosensors

are cited as variable reproducibility, high limits of detection, and problems with nonspecific binding (84, 85). However, with continued improvements and the advancement of miniaturization of equipment, EIS has become an increasingly attractive technique in biosensor applications. In general, impedance (Z) is complex phenomenon which can be correlated directly with analyte binding to a biosensor surface. Usually, Z is recorded over a wide range of frequency with respect to time, where two major components, i.e., resistance (R) and capacitance (C), are measured. Impedance data are often represented as Nyquist plots, where R is termed the “real component of impedance” on the x axis and C is termed the “imaginary component of impedance” on the y axis. A typical Nyquist plot is semicircular, with a 45-degree rise sometimes observed at the low-frequency end (Fig. 3B).

At high frequency, the major component of impedance derives from the resistance from solution itself (solution resistance [R_s]), whereas at lower frequency, impedance arises from the resistance to the flow of electrons or charge close to the electrode surface (charge transfer resistance [R_{ct}]). The Nyquist plot can be translated into an equivalent circuit model proposed by Randles (18), where it is easy to isolate each individual component (Fig. 3A). Changes in impedance arising from increasing deposition on the sensor surface, upon either layer-by-layer sensor construction or analyte binding, can be plotted quantitatively (Fig. 3C).

Impedimetric detection of an analyte can be achieved in the presence or absence of an additional electron/redox mediator. In the presence of electron mediators such as $\text{Ru}(\text{NH}_3)_6^{3+/2+}$ (hexammineruthenium III/II ions) and $\text{Fe}(\text{CN})_6^{3-/4-}$ (ferricyanide/ferrocyanide), the impedance is termed Faradaic impedance. In the absence of mediators, the observed impedance is called non-Faradaic impedance. The use of electron mediators ensures a plentiful supply of redox species to ensure that impedance does not become limited. Although impedance measurement is straightforward, the complexity depends on the choice of electrode material, base layer construction (type of self-assembled monolayer [SAM] or polymers), bioreceptor conjugation chemistry, type and size of analytes, and complexity of the sample matrix. These issues have turned the research focus toward optimizing layer-by-layer sensor construction to achieve the optimum impedance signal with minimum noise.

A plethora of reports detailing the impedimetric detection of whole bacterial cells has emerged in recent years (Fig. 1). Most of these studies have focused upon detection of the model organism *E. coli* (26, 87), although other bacteria have also been detected, including sulfate-reducing bacteria (88), *Salmonella* Typhimurium (89), *Campylobacter jejuni* (90), and *Staphylococcus aureus* (91). The reported sensor construction varies widely in the selection of base electrode materials, choice of bioreceptor, linking chemistry, and finally impedance data representation. The most common way of presenting data is the change in R_{ct} upon analyte addition (raw R_{ct} change or percent change); however, plotting real impedance, imaginary impedance, or absolute impedance against bacterial concentration is also employed. Chrono-impedimetric data can also be obtained by taking measurements at a fixed frequency to monitor real-time binding.

A comprehensive list of published impedimetric sensors to detect whole bacteria is presented in Table 6. Here, several recent case studies are discussed in more detail, based on their advantages and novel features, including choice of electrode material, trans-

ducer surface functionalization, choice of conjugation strategies, and readout methods.

The detection of viable cells in mixed populations of live and dead cells of *E. coli* has been reported (99). Differentiating live cells from dead cells can be advantageous when the number of viable cells reflects the true pathogenic count. In this study, immunosensors were generated upon polycrystalline silicon interdigitated electrodes. Usually, viable cells are voluminous compared to dead cells. As live cells have a higher cell volume, their interference with the electric field is higher than that of the dead cells, which can be detected by impedance and capacitance measurement. The limit of detection for the sensor was 3×10^2 CFU/ml, and a similar signal was achieved in the presence of a large excess of dead cells, although this system has not been validated using biologically relevant samples. The more sensitive, non-Faradaic impedimetric detection of *E. coli* was achieved using a biotinylated whole antibody as a bioreceptor (96). Biotinyl antibodies were tethered to the biotin-presenting mixed SAM (mSAM) on a gold surface via a NeutrAvidin linkage. The sensor system gave a low detection limit of 10 CFU/ml for whole cells and was also validated by SPR. Again, however, the system was not validated in biologically relevant samples.

The use of a novel electrode material, reduced graphene oxide paper, in the construction of a nanoparticle-based immunosensor for detection of *E. coli* has been reported (102). Antibodies were immobilized upon electrodeposited gold nanoparticles using a biotin-streptavidin link. The sensor yielded a detection limit of 10^2 cells/ml with high selectivity and lower detection limits of 10^4 cells/ml and 10^3 cells/ml in contaminated ground beef and cucumber samples, respectively. This system shows promise for operation in relevant sample matrices.

Bacteriophages have high specificity toward bacteria, which makes them an attractive natural bioreceptor. In a recent study, bacteriophages were chemically tethered to SAM-functionalized gold electrodes to quantify *E. coli* cells (101). The sensor displayed a good detection limit of 8×10^2 CFU/ml in less than 15 min. The sensor performance was further validated by loop-mediated isothermal amplification (LAMP) of the *E. coli tuf* gene after cell lysis and quantitation using linear sweep voltammetry.

In a novel approach, antibody-tagged biofunctional magnetic beads were used to facilitate the migration of target bacteria to the sensor surface, (92). The immunosensor was constructed on silanized, nonporous alumina, which was separated by two compartments with fluid accessibility. Platinum wire working and reference electrodes were placed in two compartments, an unusual approach where the sensor surface was not set as the working electrode area. The antibody-coated magnetic beads with bound bacterial cells were magnetically transported on top of the alumina immunosensor surface to allow for binding. After immunoreaction, the magnetic field was removed, excess beads were washed away, and impedance readings were taken. This impedimetric method achieved a higher binding capability than the nonconcentrating method and a lower detection limit of 10 CFU/ml. Although the system is innovative, its complicated setup makes it difficult to translate into a point-of-care application.

Impedimetric detection of sulfate-reducing bacteria (SRB) was reported using nickel foam as working electrode material (105). The nickel foam has regular porous grooves; gold nanoparticles were deposited within these pores, followed by 11-mercaptopundecanoic acid (MPA) SAM-tethered antibodies. The sensor had a

TABLE 6 Examples of impedimetric electrochemical biosensors for detection of whole bacterial cells^a

Bacterium(a)	Transducer	Chemistry	Bioreceptor	LOD	Reference
<i>E. coli</i> O157:H7	Gold	EDC/NHS	Antibody	2 CFU/ml	26
<i>E. coli</i> O157:H7	Nanoporous aluminum oxide membrane	Trimethoxysilane-HA-EDC/NHS	Antibody	10 CFU/ml	27
<i>E. coli</i> O157:H7	Nanoporous aluminum oxide membrane	Silane-PEG	Antibody	10 CFU/ml	92
<i>E. coli</i> K-12	Gold microelectrode, interdigitated	Physisorption	T4 bacteriophage	10 ⁴ –10 ⁷ CFU/ml	87
<i>E. coli</i> K-12	Boron-doped UNCD microelectrode array	Physisorption	Antibody	NA	93
<i>E. coli</i> O157:H7	Gold microelectrode, interdigitated	Physisorption	Antibody	2.5 × 10 ⁴ CFU/ml and 2.5 × 10 ⁷ CFU/ml	94
<i>E. coli</i>	Gold	SAM-EDC/NHS	Antibody	1.0 × 10 ³ CFU/ml	95
<i>E. coli</i>	Gold electrode	SAM-biotin-NeutrAvidin	Biotinyl antibody	10 CFU/ml	96
<i>E. coli</i>	7% gold-tungsten plate wire	Polyethyleneamine-streptavidin	Biotinyl antibody	10 ³ –10 ⁸ CFU/ml	97
<i>E. coli</i>	Gold disk	mSAM	Synthetic glycan	10 ² –10 ³ CFU/ml	98
<i>E. coli</i>	Polysilicon interdigitated electrodes	Glutaraldehyde	Antibody	3 × 10 ² CFU/ml	99
<i>E. coli</i> O157:H7	Gold	SAM-HA-EDC/NHS	Antibody	7 CFU/ml	100
<i>E. coli</i>	Gold	SAM-PDICT cross-linker	Bacteriophage	8 × 10 ² CFU/ml	101
<i>E. coli</i>	Graphene paper	Biotin-streptavidin	Antibody	1.5 × 10 ² CFU/ml	102
<i>E. coli</i>	Screen-printed carbon microarrays	EDC/NHS	Bacteriophage	10 ⁴ CFU/ml for 50-μl samples	103
Sulfate-reducing bacteria	Glassy carbon	Reduced graphene sheet with chitosan plus 1% glutaraldehyde	Antibody	1.8 × 10 ¹ –1.8 × 10 ⁷ CFU/ml	88
Sulfate-reducing bacteria	ITO	Chitosan-reduced grapheme sheet	Bioimprint of bacteria	1.0 × 10 ⁴ –1.0 × 10 ⁸ CFU/ml	104
Sulfate-reducing bacteria	Foam Ni	Nanoparticle-SAM-EDC/NHS	Antibody	2.1 × 10 ¹ –2.1 × 10 ⁷ CFU/ml	105
<i>Salmonella</i> Typhimurium	Gold	SAM-glutaraldehyde	Antibody	NA	89
<i>Salmonella</i> Typhimurium	Electroplated gold on disposable printed circuit board	16-MHDA-EDC-NHS	Monoclonal antibody	10 CFU in 100 ml	106
<i>Salmonella</i> Typhimurium	Gold	Polytyramine-glutaraldehyde	Antibody	NA	107
<i>Campylobacter jejuni</i>	Glassy carbon	Physisorped onto <i>O</i> -carboxymethylchitosan surface-modified Fe ₃ O ₄ nanoparticles	Monoclonal antibody	1.0 × 10 ³ –1.0 × 10 ⁷ CFU/ml	90
<i>Listeria innocua</i>	Gold	SAM-EDC/NHS	Endolysin (bacteriophage-encoded peptidoglycan hydrolases)	1.1 × 10 ⁴ and 10 ⁵ CFU/ml	30
<i>Staphylococcus aureus</i>	Nanoporous alumina	Silane–1% GPMS	Antibody	10 ² CFU/ml	91
<i>Porphyromonas gingivalis</i> , <i>E. coli</i>	Microfluidic cell with hydrodynamic focusing	No immobilization/impedance reading during flow of cells	None	10 ³ cells/ml	108

^a Abbreviations: EDC, ethyl(dimethylaminopropyl) carbodiimide; PEG, polyethylene glycol; UNCD, ultrananocrystalline diamond; NA, not available; PDICT, 1,4-dithiocyanate; ITO, indium tin oxide; mSAM, mixed self-assembled monolayer; NHS, *N*-hydroxysuccinimide; SAM, self-assembled monolayer; MHDA, mecaptohexadecanoic acid; GPMS, (3-glycidoxypropyl)trimethoxysilane.

detection range of 2.1 × 10¹ to 2.1 × 10⁷ CFU/ml with good selectivity over other strains. In another approach for SRB detection, a bioimprinting technique was used (104). In this method, biomolecules or cells can be deposited on a surface and then washed off, leaving their imprint on the surface. Briefly, multilayer reduced graphene sheets and chitosan were electrodeposited upon indium tin oxide (ITO), followed by absorption of SRB and a thin coating layer of nonconducting chitosan around the bacteria. SRB were then washed off the surface to get the bioimprint on biosensor surface. This imprint was able to capture and quantify target SRB in a range of 10⁴ to 10⁸ CFU/ml using EIS. It was also able to distinguish other control strains based on size and shape differ-

ences, but the authors recommended its use with other bioreceptor combinations.

Monoclonal antibodies are highly specific compared to polyclonal antibodies, offering higher sensitivity and selectivity for analyte detection. *Salmonella* Typhimurium has been detected by EIS using monoclonal antibodies as bioreceptors on a gold-plated disposable circuit board (106). The monoclonal antibodies were raised against *Salmonella* Typhimurium cell surface lipopolysaccharide (LPS), and the impedance signal at 10 Hz was able to detect the 10 bacteria in 100 ml of sample.

Although a variety of techniques are being employed to detect whole bacteria, the key challenges being faced are sensitivity, re-




FIG 4 Technology translation: a summary of the current research priorities in order to bring laboratory-based biosensors for bacterial detection to market.

producibility, and miniaturization before their successful translation as a commercial product. Impedance-based biosensing shows great promise, being highly sensitive and label free. However, the present research needs to be taken forward with an emphasis on reproducible, inexpensive, and novel electrode material, stable conjugation, and strict optimization of bioreceptor configuration, orientation, and concentration. Miniaturization of impedance systems and robotic layer-by-layer construction will ultimately improve sensor performance with high reproducibility for commercialization.

CONCLUSIONS AND FUTURE PERSPECTIVES

There is a growing need for rapid and sensitive detection of bacteria, in complex samples, at the point of interest. In spite of the impressive research output in recent years, detailing specific and sensitive laboratory-based biosensor systems for the detection of bacteria, the manufacture of commercially available systems for point-of-interest application is seriously lagging behind. This is due to the issues discussed above: (i) difficulty in achieving specificity and sensitivity in complex “real-world” samples such as blood, feces, food, etc.; (ii) difficulties in reducing the size and cost of certain systems, for instance, SPR, QCM, and cantilever-based sensors; and (iii) improving the reliability of the system with novel manufacturing methods. Around 200 companies are now working in the area of biosensors and bioelectronics (109); however, the major driving force behind the commercial market (85%) is still for blood glucose monitoring.

In order to bring laboratory-based biosensor systems to market, strong collaboration between academia and industry is required to address the key issues highlighted in Fig. 4. Selection of inexpensive, reproducible, electrochemically favorable, and chemically stable base material is the initial important step toward commercial electrochemical biosensors. A wide range of base materials either alone or in combination have been explored. However, their individual suitability for particular sensor systems needs to be assessed carefully. As discussed in this paper, recent advances in transducer surface nanoengineering (e.g., increasing surface area using nanoparticles or nanofibers and the use of magnetic nanoparticles in sandwich-type assays) have shown promise in terms of boosting the sensor signal. This is important where detection of just a few bacterial cells is required. Base layers, e.g.,

polymers or self-assembled monolayers on which bioreceptors are immobilized, can have an influence on the electrochemical signal as well as nonspecific binding. Their thickness, surface charge, and chemical groups can be intelligently tuned for enhanced performance.

Equally, the development of novel bioreceptors, including bacteriophages, non-antibody binding proteins, half-antibodies, and single-chain (camelid) antibodies, offers higher specificity, which is a key advantage for detecting bacteria in complex matrices which contain many potential interferents, including human cells and commensal bacteria as well as many proteins and metabolites. Although antibodies are the most widely used bioreceptors in affinity biosensor research, their production and purification costs and stability during and after immobilization on sensor surface can be challenging. The shelf life of these antibodies on the sensor surface is not significantly long, and binding efficiency tends to decrease over time. To overcome some of these deficiencies, recent advances in engineered antibody mimetics include peptoid nano-sheets (110), where antibody mimetic peptoids are self-assembled to form 3- to 5-nm-thick sheets with surface loops expressing antigen binding sites. They are chemically and biologically stable and can be produced with ease and precise control. Other remarkable engineered antibody alternatives include single-chain variable fragments (ScFv) (111), camelid-derived heavy variable-chain (VHH) antibodies (nanobodies) (112, 113), single-chain antibodies expressed via yeast surface display (114), DARPins (115), and other artificial proteins such as adhirons (116). The advantages of these alternatives are that they are comparatively small, easily customized, and conveniently mass produced in bacterial systems, avoiding traditional antibody production in mammals or birds.

Two other important aspects are regeneration of the sensor surface and multiplexing, where many bacteria can be analyzed simultaneously. Regeneration can be cost-effective, and successful regeneration can be possible with the above-mentioned stable bioreceptors, since they can often withstand harsh regeneration buffers without compromising binding capacity. Parallel multiplexing on a single chip can also reduce detection costs, providing multiple items of information from a single-shot analysis. However, all of these advancements again demand large-scale optimization, which is basically limited by funding.

Screen printing of electrodes *en masse* is now improving biosensor reliability. Companies making commercially available screen-printed electrodes are growing and include Metrohm USA Inc. (United States), DropSens S.L. (Spain), Gwent Sensors Ltd. (United Kingdom), Bio-Logic SAS (France), Kanichi Research Ltd. (United Kingdom), BVT Technologies Ltd. (Czech Republic), and Quasense Company Ltd. (Thailand) (18). In terms of electrochemical biosensing, specialist companies such as Uniscan Instruments Ltd. are supplying commercially available software and systems to integrate sensor chips with signal processing and readout.

However, to date, only a few commercially available biosensor systems have been employed for the detection of bacteria (117); these include SPR-based optical biosensors (Biacore), the potentiometric threshold immunoassay system (Molecular Devices Corporation), and the PCR-based universal biosensor, which employs mass spectrometry as a detection method (Ibis, San Diego, CA, USA). The immunoassay-based sensor is the only one of these that has been employed for whole bacterial cell detection (118), although this and the other sensors require sample processing. The Biacore devices and mass spectrometry-based systems are bulky and costly and require specialist users. Electrochemical methodologies offer lower manufacturing costs and ease of system miniaturization and integration, with impedance spectroscopy becoming increasingly popular due to the lack of reagents and ability to detect any analyte without the need for electroactive species. However, a commercially available impedimetric biosensor is still awaited. Unlike glucose biosensors, where sample and device size has been significantly optimized over years and a tiny blood drop can directly be tested, an impedance biosensor against bacteria might include a single dilution step before testing, depending on the detection sample. This will reduce the noise from the biological sample and produce ample volume to incubate the chip. Chip architecture and device design will also be crucial to have a user-friendly end user device.

In conclusion, the market demand and research trends presented in this review clearly demonstrate the importance of handheld, user-friendly biosensors for whole bacterial cell detection. Electrochemical biosensors, more specifically, impedimetric sensors, can take the leading position in this area. However, the appropriate miniaturization, optimization, and clinical trials need to be done before any product is launched into market. Advancements in nanobiotechnology and biomolecular engineering and developments in particle research are moving this field quickly toward its destination. The widespread use of whole bacterial cell biosensors not only will be a milestone in the biosensor industry but will have a profound impact on food, medical, environmental, and clinical diagnostics.

ACKNOWLEDGMENTS

Asif Ahmed is funded by a University of Leeds Fully-Funded International Research Scholarship (FIRS). Natalie A. Hirst received funding from the Leeds Teaching Hospitals NHS Trust Charitable Foundation and the Bowel Disease Research Foundation.

We thank Jack Goode for photographic assistance with preparing the figures.

REFERENCES

1. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM. 2011. Foodborne illness acquired in the United

- States—major pathogens. *Emerg. Infect. Dis.* 17:7–15. <http://dx.doi.org/10.3201/eid1701.P11101>.
2. Sharma H, Mutharasan R. 2013. Review of biosensors for foodborne pathogens and toxins. *Sensors Actuat. B Chem.* 183:535–549. <http://dx.doi.org/10.1016/j.snb.2013.03.137>.
3. Fournier P-E, Drancourt M, Colson P, Rolain J-M, Scola BL, Raoult D. 2013. Modern clinical microbiology: new challenges and solutions. *Nat. Rev. Microbiol.* 11:574–585. <http://dx.doi.org/10.1038/nrmicro3068>.
4. Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. 2013. Recent advances in understanding enteric pathogenic *Escherichia coli*. *Clin. Microbiol. Rev.* 26:822–880. <http://dx.doi.org/10.1128/CMR.00022-13>.
5. Burnham CA, Carroll KC. 2013. Diagnosis of *Clostridium difficile* infection: an ongoing conundrum for clinicians and for clinical laboratories. *Clin. Microbiol. Rev.* 26:604–630. <http://dx.doi.org/10.1128/CMR.00016-13>.
6. Espy MJ, Uhl JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA, Yao JD, Wengenack NL, Rosenblatt JE, Cockerill FR, III, Smith TF. 2006. Real-time PCR in clinical microbiology: applications for routine laboratory testing. *Clin. Microbiol. Rev.* 19:165–256. <http://dx.doi.org/10.1128/CMR.19.1.165-256.2006>.
7. van de Beek D, de Gans J, Tunkel AR, Wijdicks EFM. 2006. Community-acquired bacterial meningitis in adults. *N. Engl. J. Med.* 354:44–53. <http://dx.doi.org/10.1056/NEJMr052116>.
8. Peeling RW, Holmes KK, Mabey D, Ronald A. 2006. Rapid tests for sexually transmitted infections (STIs): the way forward. *Sex. Transm. Infect.* 82:V1–V6. <http://dx.doi.org/10.1136/sti.2006.024265>.
9. Segal M. 1988. Invisible villains; tiny microbes are biggest food hazard. *FDA consumer.* <http://www.highbeam.com/doc/1G1-6589512.html>.
10. Gooding JJ. 2006. Biosensor technology for detecting biological warfare agents: recent progress and future trends. *Anal. Chim. Acta* 559:137–151. <http://dx.doi.org/10.1016/j.aca.2005.12.020>.
11. Carroll KC. 2002. Laboratory diagnosis of lower respiratory tract infections: controversy and conundrums. *J. Clin. Microbiol.* 40:3115–3120. <http://dx.doi.org/10.1128/JCM.40.9.3115-3120.2002>.
12. Barletta F, Mercado EH, Lluque A, Ruiz J, Cleary TG, Ochoa TJ. 2013. Multiplex real-time PCR for detection of campylobacter, salmonella, and shigella. *J. Clin. Microbiol.* 51:2822–2829. <http://dx.doi.org/10.1128/JCM.01397-13>.
13. Pfeiffer ML, DuPont HL, Ochoa TJ. 2012. The patient presenting with acute dysentery—a systematic review. *J. Infect.* 64:374–386. <http://dx.doi.org/10.1016/j.jinf.2012.01.006>.
14. Boehme CC, Saacks S, O'Brien RJ. 2013. The changing landscape of diagnostic services for tuberculosis. *Semin. Respir. Crit. Care Med.* 34:17–31. <http://dx.doi.org/10.1055/s-0032-1333468>.
15. Bamberger DM. 2010. Diagnosis, initial management, and prevention of meningitis. *Am. Fam. Physician* 82:1491–1498. <http://www.aafp.org/afp/2010/1215/p1491.html>.
16. Su W-H, Tsou T-S, Chen C-S, Ho T-Y, Lee W-L, Yu Y-Y, Chen T-J, Tan C-H, Wang P-H. 2011. Are we satisfied with the tools for the diagnosis of gonococcal infection in females? *J. Chin. Med. Assoc.* 74:430–434. <http://dx.doi.org/10.1016/j.jcma.2011.08.012>.
17. Read PJ, Donovan B. 2012. Clinical aspects of adult syphilis. *Intern. Med. J.* 42:614–620. <http://dx.doi.org/10.1111/j.1445-5994.2012.02814.x>.
18. Rushworth JV, Hirst NA, Goode JA, Pike DJ, Ahmed A, Millner PA. 2013. Impedimetric biosensors for medical applications: current progress and challenges. *ASME*, New York, NY.
19. Paniel N, Baudart J. 2013. Colorimetric and electrochemical genosensors for the detection of *Escherichia coli* DNA without amplification in seawater. *Talanta* 115:133–142. <http://dx.doi.org/10.1016/j.talanta.2013.04.050>.
20. Anderson MJ, Miller HR, Alocija EC. 2013. PCR-less DNA copolymerization detection of Shiga like toxin 1 (stx1) in *Escherichia coli* O157:H7. *Biosens. Bioelectron.* 42:581–585. <http://dx.doi.org/10.1016/j.bios.2012.09.068>.
21. Gerasimova YV, Kolpashchikov DM. 2013. Detection of bacterial 16S rRNA using a molecular beacon-based X sensor. *Biosens. Bioelectron.* 41:386–390. <http://dx.doi.org/10.1016/j.bios.2012.08.058>.
22. Foudeh AM, Daoud JT, Faucher SP, Veres T, Tabrizian M. 2014. Sub-femtomole detection of 16s rRNA from *Legionella pneumophila* using surface plasmon resonance imaging. *Biosens. Bioelectron.* 52:129–135. <http://dx.doi.org/10.1016/j.bios.2013.08.032>.

23. Miranda OR, Li X, Garcia-Gonzalez L, Zhu Z-J, Yan B, Bunz UHF, Rotello VM. 2011. Colorimetric bacteria sensing using a supramolecular enzyme-nanoparticle biosensor. *J. Am. Chem. Soc.* 133:9650–9653. <http://dx.doi.org/10.1021/ja2021729>.
24. Farrow B, Hong SA, Romero EC, Lai B, Coppock MB, Deyle KM, Finch AS, Stratis-Cullum DN, Agnew HD, Yang S, Heath JR. 2013. A chemically synthesized capture agent enables the selective, sensitive, and robust electrochemical detection of anthrax protective antigen. *ACS Nano* 7:9452–9460. <http://dx.doi.org/10.1021/nn404296k>.
25. Johnson JL, Rose BE, Sharar AK, Ransom GM, Lattuada CP, McNamara AM. 1995. Methods used for detection and recovery of *Escherichia coli* O157h7 associated with a food-borne disease outbreak. *J. Food Prot.* 58:597–603.
26. Barreiros dos Santos M, Aguil JP, Prieto-Simón B, Sporer C, Teixeira V, Samitier J. 2013. Highly sensitive detection of pathogen *Escherichia coli* O157:H7 by electrochemical impedance spectroscopy. *Biosens. Bioelectron.* 45:174–180. <http://dx.doi.org/10.1016/j.bios.2013.01.009>.
27. Joung C-K, Kim H-N, Lim M-C, Jeon T-J, Kim H-Y, Kim Y-R. 2013. A nanoporous membrane-based impedimetric immunosensor for label-free detection of pathogenic bacteria in whole milk. *Biosens. Bioelectron.* 44:210–215. <http://dx.doi.org/10.1016/j.bios.2013.01.024>.
28. Serra B, Gamella M, Reviejo AJ, Pingarron JM. 2008. Lectin-modified piezoelectric biosensors for bacteria recognition and quantification. *Anal. Bioanal. Chem.* 391:1853–1860. <http://dx.doi.org/10.1007/s00216-008-2141-6>.
29. Wang Y, Ye Z, Si C, Ying Y. 2013. Monitoring of *Escherichia coli* O157:H7 in food samples using lectin based surface plasmon resonance biosensor. *Food Chem.* 136:1303–1308. <http://dx.doi.org/10.1016/j.foodchem.2012.09.069>.
30. Tolba M, Ahmed MU, Tlili C, Eichenseher F, Loessner MJ, Zourob M. 2012. A bacteriophage endolysin-based electrochemical impedance biosensor for the rapid detection of *Listeria* cells. *Analyst* 137:5749–5756. <http://dx.doi.org/10.1039/c2an35988j>.
31. Tawil N, Sacher E, Mandeville R, Meunier M. 2012. Surface plasmon resonance detection of *E. coli* and methicillin-resistant *S. aureus* using bacteriophages. *Biosens. Bioelectron.* 37:24–29. <http://dx.doi.org/10.1016/j.bios.2012.04.048>.
32. Ricci F, Volpe G, Micheli L, Pallechi G. 2007. A review on novel developments and applications of immunosensors in food analysis. *Anal. Chim. Acta* 605:111–129. <http://dx.doi.org/10.1016/j.aca.2007.10.046>.
33. Wang YX, Ye ZZ, Ying YB. 2012. New trends in impedimetric biosensors for the detection of foodborne pathogenic bacteria. *Sensors* 12:3449–3471. <http://dx.doi.org/10.3390/s120303449>.
34. Fan X, White IM, Shopova SI, Zhu H, Suter JD, Sun Y. 2008. Sensitive optical biosensors for unlabeled targets: a review. *Anal. Chim. Acta* 620:8–26. <http://dx.doi.org/10.1016/j.aca.2008.05.022>.
35. Ligler FS, Sapsford KE, Golden JP, Shriver-Lake LC, Taitt CR, Dyer MA, Barone S, Myatt CJ. 2007. The array biosensor: portable, automated systems. *Anal. Sci.* 23:5–10. <http://dx.doi.org/10.2116/analsci.23.5>.
36. Geng T, Uknalis J, Tu SI, Bhunia AK. 2006. Fiber-optic biosensor employing Alexa-Fluor conjugated antibody for detection of *Escherichia coli* O157:H7 from ground beef in four hours. *Sensors* 6:796–807. <http://dx.doi.org/10.3390/s6080796>.
37. Moufouk F, Rosa da Costa AM, Martins J, Zourob M, Abu-Salah KM, Alrokayan SA. 2011. Development of a highly sensitive bacteria detection assay using fluorescent pH-responsive polymeric micelles. *Biosens. Bioelectron.* 26:3517–3523. <http://dx.doi.org/10.1016/j.bios.2011.01.037>.
38. Owen V. 1997. Real-time optical immunosensors—a commercial reality. *Biosens. Bioelectron.* 12:i-ii.
39. Wang Y, Knoll W, Dostalek J. 2012. Bacterial pathogen surface plasmon resonance biosensor advanced by long range surface plasmons and magnetic nanoparticle assays. *Anal. Chem.* 84:8345–8350. <http://dx.doi.org/10.1021/ac301904x>.
40. Baccar H, Mejri MB, Hafaiedh I, Ktari T, Aouni M, Abdelghani A. 2010. Surface plasmon resonance immunosensor for bacteria detection. *Talanta* 82:810–814. <http://dx.doi.org/10.1016/j.talanta.2010.05.060>.
41. Tripathi SM, Bock WJ, Mikulic P, Chinnappan R, Ng A, Tolba M, Zourob M. 2012. Long period grating based biosensor for the detection of *Escherichia coli* bacteria. *Biosens. Bioelectron.* 35:308–312. <http://dx.doi.org/10.1016/j.bios.2012.03.006>.
42. Gasparyan VK, Bazukyan IL. 2013. Lectin sensitized anisotropic silver nanoparticles for detection of some bacteria. *Anal. Chim. Acta* 766:83–87. <http://dx.doi.org/10.1016/j.aca.2012.12.015>.
43. Torun O, Boyaci IH, Temur E, Tamer U. 2012. Comparison of sensing strategies in SPR biosensor for rapid and sensitive enumeration of bacteria. *Biosens. Bioelectron.* 37:53–60. <http://dx.doi.org/10.1016/j.bios.2012.04.034>.
44. Sepulveda B, Angelome PC, Lechuga LM, Liz-Marzan LM. 2009. LSPR-based nanobiosensors. *Nano Today* 4:244–251. <http://dx.doi.org/10.1016/j.nantod.2009.04.001>.
45. Charlermroj R, Oplatowska M, Gajanandana O, Himananto O, Grant IR, Karoonuthaisiri N, Elliott CT. 2013. Strategies to improve the surface plasmon resonance-based immunodetection of bacterial cells. *Microchim. Acta* 180:643–650. <http://dx.doi.org/10.1007/s00604-013-0975-x>.
46. Wang C, Irudayaraj J. 2008. Gold nanorod probes for the detection of multiple pathogens. *Small* 4:2204–2208. <http://dx.doi.org/10.1002/sml.200800309>.
47. Fu JX, Park B, Zhao YP. 2009. Limitation of a localized surface plasmon resonance sensor for *Salmonella* detection. *Sensors Actuat. B Chem.* 141:276–283. <http://dx.doi.org/10.1016/j.snb.2009.06.020>.
48. Ray PC, Khan SA, Singh AK, Senapati D, Fan Z. 2012. Nanomaterials for targeted detection and photothermal killing of bacteria. *Chem. Soc. Rev.* 41:3193–3209. <http://dx.doi.org/10.1039/c2cs15340h>.
49. Cheng IF, Chang HC, Chen TY, Hu CM, Yang FL. 2013. Rapid (<5 min) identification of pathogen in human blood by electrokinetic concentration and surface-enhanced Raman spectroscopy. *Sci. Rep.* 3:2365. <http://dx.doi.org/10.1038/srep02365>.
50. Ohk S-H, Bhunia AK. 2013. Multiplex fiber optic biosensor for detection of *Listeria monocytogenes*, *Escherichia coli* O157:H7 and *Salmonella enterica* from ready-to-eat meat samples. *Food Microbiol.* 33:166–171. <http://dx.doi.org/10.1016/j.fm.2012.09.013>.
51. Ohk SH, Koo OK, Sen T, Yamamoto CM, Bhunia AK. 2010. Antibody-aptamer functionalized fibre-optic biosensor for specific detection of *Listeria monocytogenes* from food. *J. Appl. Microbiol.* 109:808–817. <http://dx.doi.org/10.1111/j.1365-2672.2010.04709.x>.
52. Massad-Ivanir N, Shtenberg G, Tzur A, Krepker MA, Segal E. 2011. Engineering nanostructured porous SiO₂ surfaces for bacteria detection via “direct cell capture.” *Anal. Chem.* 83:3282–3289. <http://dx.doi.org/10.1021/ac200407w>.
53. Fronczek CF, You DJ, Yoon J-Y. 2013. Single-pipetting microfluidic assay device for rapid detection of *Salmonella* from poultry package. *Biosens. Bioelectron.* 40:342–349. <http://dx.doi.org/10.1016/j.bios.2012.07.076>.
54. Yang X, Gu C, Qian F, Li Y, Zhang JZ. 2011. Highly sensitive detection of proteins and bacteria in aqueous solution using surface-enhanced Raman scattering and optical fibers. *Anal. Chem.* 83:5888–5894. <http://dx.doi.org/10.1021/ac200707t>.
55. Arlett JL, Myers EB, Roukes ML. 2011. Comparative advantages of mechanical biosensors. *Nat. Nanotechnol.* 6:203–215. <http://dx.doi.org/10.1038/nnano.2011.44>.
56. Jiang X, Wang R, Wang Y, Su X, Ying Y, Wang J, Li Y. 2011. Evaluation of different micro/nanobeads used as amplifiers in QCM immunosensor for more sensitive detection of *E. coli* O157:H7. *Biosens. Bioelectron.* 29:23–28. <http://dx.doi.org/10.1016/j.bios.2011.07.059>.
57. Guo X, Lin C-S, Chen S-H, Ye R, Wu VCH. 2012. A piezoelectric immunosensor for specific capture and enrichment of viable pathogens by quartz crystal microbalance sensor, followed by detection with antibody-functionalized gold nanoparticles. *Biosens. Bioelectron.* 38:177–183. <http://dx.doi.org/10.1016/j.bios.2012.05.024>.
58. Salam F, Uludag Y, Tohill IE. 2013. Real-time and sensitive detection of *Salmonella* Typhimurium using an automated quartz crystal microbalance (QCM) instrument with nanoparticles amplification. *Talanta* 115:761–767. <http://dx.doi.org/10.1016/j.talanta.2013.06.034>.
59. Yakovleva ME, Moran AP, Safina GR, Wadstrom T, Danielsson B. 2011. Lectin typing of *Campylobacter jejuni* using a novel quartz crystal microbalance technique. *Anal. Chim. Acta* 694:1–5. <http://dx.doi.org/10.1016/j.aca.2011.03.014>.
60. Hao R, Wang D, Zhang X, Zuo G, Wei H, Yang R, Zhang Z, Cheng Z, Guo Y, Cui Z, Zhou Y. 2009. Rapid detection of *Bacillus anthracis* using monoclonal antibody functionalized QCM sensor. *Biosens. Bioelectron.* 24:1330–1335. <http://dx.doi.org/10.1016/j.bios.2008.07.071>.
61. Buchapudi KR, Huang X, Yang X, Ji HF, Thundat T. 2011. Microcan-

- tilever biosensors for chemicals and bioorganisms. *Analyst* 136:1539–1556. <http://dx.doi.org/10.1039/c0an01007c>.
62. Lang HP, Gerber C. 2008. Microcantilever sensors. *Top. Curr. Chem.* 285:1–27. http://dx.doi.org/10.1007/128_2007_28.
 63. Zhang J, Ji HF. 2004. An anti *E. coli* O157:H7 antibody-immobilized microcantilever for the detection of *Escherichia coli* (*E. coli*). *Anal. Sci.* 20:585–587. <http://dx.doi.org/10.2116/analsci.20.585>.
 64. Campbell GA, Mutharasan R. 2005. Detection of pathogen *Escherichia coli* O157:H7 using self-excited PZT-glass microcantilevers. *Biosens. Bioelectron.* 21:462–473. <http://dx.doi.org/10.1016/j.bios.2004.11.009>.
 65. Zhu Q, Shih WY, Shih WH. 2007. In situ, in-liquid, all-electrical detection of *Salmonella typhimurium* using lead titanate zirconate/gold-coated glass cantilevers at any dipping depth. *Biosens. Bioelectron.* 22:3132–3138. <http://dx.doi.org/10.1016/j.bios.2007.02.005>.
 66. Sungkanak U, Sappat A, Wisitsoraat A, Promptmas C, Tuantranont A. 2010. Ultrasensitive detection of *Vibrio cholerae* O1 using microcantilever-based biosensor with dynamic force microscopy. *Biosens. Bioelectron.* 26:784–789. <http://dx.doi.org/10.1016/j.bios.2010.06.024>.
 67. Ji HF, Yan XD, Zhang J, Thundat T. 2004. Molecular recognition of bio warfare agents using micromechanical sensors. *Expert Rev. Mol. Diagn.* 4:859–866. <http://dx.doi.org/10.1586/14737159.4.6.859>.
 68. Campbell GA, Mutharasan R. 2007. A method of measuring *Escherichia coli* O157:H7 at 1 cell/mL in 1 liter sample using antibody functionalized piezoelectric-excited millimeter-sized cantilever sensor. *Environ. Sci. Technol.* 41:1668–1674. <http://dx.doi.org/10.1021/es061947p>.
 69. Sharma H, Mutharasan R. 2013. Rapid and sensitive immunodetection of *Listeria monocytogenes* in milk using a novel piezoelectric cantilever sensor. *Biosens. Bioelectron.* 45:158–162. <http://dx.doi.org/10.1016/j.bios.2013.01.068>.
 70. Longo G, Alonso-Sarduy L, Rio LM, Bizzini A, Trampuz A, Notz J, Dietler G, Kasas S. 2013. Rapid detection of bacterial resistance to antibiotics using AFM cantilevers as nanomechanical sensors. *Nat. Nanotechnol.* 8:522–526. <http://dx.doi.org/10.1038/nnano.2013.120>.
 71. Clark LC, Jr, Wolf R, Granger D, Taylor Z. 1953. Continuous recording of blood oxygen tensions by polarography. *J. Appl. Physiol.* 6:189–193.
 72. Korotcenkov G. 2010. *Chemical sensors, vol 1. General approaches.* Momentum Press, New York, NY.
 73. Zelada-Guillen GA, Tweed-Kent A, Niemann M, Goeringer HU, Riu J, Xavier Rius F. 2013. Ultrasensitive and real-time detection of proteins in blood using a potentiometric carbon-nanotube aptasensor. *Biosens. Bioelectron.* 41:366–371. <http://dx.doi.org/10.1016/j.bios.2012.08.055>.
 74. Wan Y, Zhang D, Hou BR. 2010. Selective and specific detection of sulfate-reducing bacteria using potentiometric stripping analysis. *Talanta* 82:1608–1611. <http://dx.doi.org/10.1016/j.talanta.2010.07.030>.
 75. Zelada-Guillen GA, Sebastian-Avila JL, Blondeau P, Riu J, Rius FX. 2012. Label-free detection of *Staphylococcus aureus* in skin using real-time potentiometric biosensors based on carbon nanotubes and aptamers. *Biosens. Bioelectron.* 31:226–232. <http://dx.doi.org/10.1016/j.bios.2011.10.021>.
 76. Laczka O, Maesa JM, Godino N, del Campo J, Fougat-Hansen M, Kutter JP, Snakenborg D, Munoz-Pascual FX, Baldrich E. 2011. Improved bacteria detection by coupling magneto-immunocapture and amperometry at flow-channel microband electrodes. *Biosens. Bioelectron.* 26:3633–3640. <http://dx.doi.org/10.1016/j.bios.2011.02.019>.
 77. Neufeld T, Schwartz-Mittelmann A, Biran D, Ron EZ, Rishpon J. 2003. Combined phage typing and amperometric detection of released enzymatic activity for the specific identification and quantification of bacteria. *Anal. Chem.* 75:580–585. <http://dx.doi.org/10.1021/ac026083e>.
 78. Li Y, Fang LC, Cheng P, Deng J, Jiang LL, Huang H, Zheng JS. 2013. An electrochemical immunosensor for sensitive detection of *Escherichia coli* O157:H7 using C-60 based biocompatible platform and enzyme functionalized Pt nanochains tracing tag. *Biosens. Bioelectron.* 49:485–491. <http://dx.doi.org/10.1016/j.bios.2013.06.008>.
 79. de Avila BEF, Pedrero M, Campuzano S, Escamilla-Gomez V, Pingarron JM. 2012. Sensitive and rapid amperometric magnetoimmunosenor for the determination of *Staphylococcus aureus*. *Anal. Bioanal. Chem.* 403:917–925. <http://dx.doi.org/10.1007/s00216-012-5738-8>.
 80. Guilbault GG, Lubrano GJ. 1973. Enzyme electrode for amperometric determination of glucose. *Anal. Chim. Acta* 64:439–455. [http://dx.doi.org/10.1016/S0003-2670\(01\)82476-4](http://dx.doi.org/10.1016/S0003-2670(01)82476-4).
 81. Wang J. 2001. Glucose biosensors: 40 years of advances and challenges. *Electroanalysis* 13:983–988. [http://dx.doi.org/10.1002/1616-8984\(200201\)10:13:0.CO;2-Q](http://dx.doi.org/10.1002/1616-8984(200201)10:13:0.CO;2-Q).
 82. Higgs SP. 2012. *Biosensors for medical applications.* Woodhead Publishing, Cambridge, United Kingdom.
 83. Kim HJ, Bennetto HP, Halablab MA, Choi CH, Yoon S. 2006. Performance of an electrochemical sensor with different types of liposomal mediators for the detection of hemolytic bacteria. *Sensors Actuat. B Chem.* 119:143–149. <http://dx.doi.org/10.1016/j.snb.2005.12.013>.
 84. Daniels JS, Pourmand N. 2007. Label-free impedance biosensors: opportunities and challenges. *Electroanalysis* 19:1239–1257. <http://dx.doi.org/10.1002/elan.200603855>.
 85. Berggren C, Bjarnason B, Johansson G. 2001. Capacitive biosensors. *Electroanalysis* 13:173–180. [http://dx.doi.org/10.1002/1521-4109\(200103\)13:3<173::AID-ELAN173>3.0.CO;2-B](http://dx.doi.org/10.1002/1521-4109(200103)13:3<173::AID-ELAN173>3.0.CO;2-B).
 86. Katz E, Willner I. 2003. Probing biomolecular interactions at conductive and semiconductive surfaces by impedance spectroscopy: routes to impedimetric immunosensors, DNA-sensors, and enzyme biosensors. *Electroanalysis* 15:913–947. <http://dx.doi.org/10.1002/elan.200390114>.
 87. Mejri MB, Baccar H, Baldrich E, Del Campo FJ, Helali S, Ktari T, Simonian A, Aouni M, Abdelghani A. 2010. Impedance biosensing using phages for bacteria detection: generation of dual signals as the clue for in-chip assay confirmation. *Biosens. Bioelectron.* 26:1261–1267. <http://dx.doi.org/10.1016/j.bios.2010.06.054>.
 88. Wan Y, Lin Z, Zhang D, Wang Y, Hou B. 2011. Impedimetric immunosensor doped with reduced graphene sheets fabricated by controllable electrodeposition for the non-labelled detection of bacteria. *Biosens. Bioelectron.* 26:1959–1964. <http://dx.doi.org/10.1016/j.bios.2010.08.008>.
 89. Mantzila AG, Maipa V, Prodromidis MI. 2008. Development of a faradic impedimetric immunosensor for the detection of *Salmonella typhimurium* in milk. *Anal. Chem.* 80:1169–1175. <http://dx.doi.org/10.1021/ac071570l>.
 90. Huang JL, Yang GJ, Meng WJ, Wu LP, Zhu AP, Jiao XA. 2010. An electrochemical impedimetric immunosensor for label-free detection of *Campylobacter jejuni* in diarrhea patients' stool based on O-carboxymethylchitosan surface modified Fe₃O₄ nanoparticles. *Biosens. Bioelectron.* 25:1204–1211. <http://dx.doi.org/10.1016/j.bios.2009.10.036>.
 91. Tan F, Leung PHM, Liu ZB, Zhang Y, Xiao LD, Ye WW, Zhang X, Yi L, Yang M. 2011. A PDMS microfluidic impedance immunosensor for *E. coli* O157:H7 and *Staphylococcus aureus* detection via antibody-immobilized nanoporous membrane. *Sensors Actuat. B Chem.* 159:328–335. <http://dx.doi.org/10.1016/j.snb.2011.06.074>.
 92. Chan KY, Ye WW, Zhang Y, Xiao LD, Leung PHM, Li Y, Yang M. 2013. Ultrasensitive detection of *E. coli* O157:H7 with biofunctional magnetic bead concentration via nanoporous membrane based electrochemical immunosensor. *Biosens. Bioelectron.* 41:532–537. <http://dx.doi.org/10.1016/j.bios.2012.09.016>.
 93. Siddiqui S, Dai ZT, Stavis CJ, Zeng HJ, Moldovan N, Hamers RJ, Carlisle JA, Arumugam PU. 2012. A quantitative study of detection mechanism of a label-free impedance biosensor using ultrananocrystalline diamond microelectrode array. *Biosens. Bioelectron.* 35:284–290. <http://dx.doi.org/10.1016/j.bios.2012.03.001>.
 94. Dweik M, Stringer RC, Dastider SG, Wu YF, Almasri M, Barizuddin S. 2012. Specific and targeted detection of viable *Escherichia coli* O157:H7 using a sensitive and reusable impedance biosensor with dose and time response studies. *Talanta* 94:84–89. <http://dx.doi.org/10.1016/j.talanta.2012.02.056>.
 95. Geng P, Zhang X, Meng W, Wang Q, Zhang W, Jin L, Feng Z, Wu Z. 2008. Self-assembled monolayers-based immunosensor for detection of *Escherichia coli* using electrochemical impedance spectroscopy. *Electrochim. Acta* 53:4663–4668. <http://dx.doi.org/10.1016/j.electacta.2008.01.037>.
 96. Maalouf R, Fournier-Wirth C, Coste J, Chebib H, Saikali Y, Vittori O, Errachid A, Cloarec JP, Martelet C, Jaffrezic-Renault N. 2007. Label-free detection of bacteria by electrochemical impedance spectroscopy: comparison to surface plasmon resonance. *Anal. Chem.* 79:4879–4886. <http://dx.doi.org/10.1021/ac070085n>.
 97. Lu L, Chee G, Yamada K, Jun S. 2013. Electrochemical impedance spectroscopic technique with a functionalized microwire sensor for rapid detection of foodborne pathogens. *Biosens. Bioelectron.* 42:492–495. <http://dx.doi.org/10.1016/j.bios.2012.10.060>.
 98. Guo XF, Kulkarni A, Doepke A, Halsall HB, Iyer S, Heineman WR.

2012. Carbohydrate-based label-free detection of *Escherichia coli* ORN 178 using electrochemical impedance spectroscopy. *Anal. Chem.* **84**: 241–246. <http://dx.doi.org/10.1021/ac202419u>.
99. de la Rica R, Baldi A, Fernandez-Sanchez C, Matsui H. 2009. Selective detection of live pathogens via surface-confined electric field perturbation on interdigitated silicon transducers. *Anal. Chem.* **81**:3830–3835. <http://dx.doi.org/10.1021/ac9001854>.
 100. Joung C-K, Kim H-N, Im H-C, Kim H-Y, Oh M-H, Kim Y-R. 2012. Ultra-sensitive detection of pathogenic microorganism using surface-engineered impedimetric immunosensor. *Sensors Actuat. B Chem.* **161**: 824–831. <http://dx.doi.org/10.1016/j.snb.2011.11.041>.
 101. Tlili C, Sokullu E, Safavieh M, Tolba M, Ahmed MU, Zourob M. 2013. Bacteria screening, viability, and confirmation assays using bacteriophage-impedimetric/loop-mediated isothermal amplification dual-response biosensors. *Anal. Chem.* **85**:4893–4901. <http://dx.doi.org/10.1021/ac302699x>.
 102. Wang YX, Ping JF, Ye ZZ, Wu J, Ying YB. 2013. Impedimetric immunosensor based on gold nanoparticles modified graphene paper for label-free detection of *Escherichia coli* O157:H7. *Biosens. Bioelectron.* **49**:492–498. <http://dx.doi.org/10.1016/j.bios.2013.05.061>.
 103. Shabani A, Zourob M, Allain B, Marquette CA, Lawrence MF, Mandeville R. 2008. Bacteriophage-modified microarrays for the direct impedimetric detection of bacteria. *Anal. Chem.* **80**:9475–9482. <http://dx.doi.org/10.1021/ac801607w>.
 104. Qi P, Wan Y, Zhang D. 2013. Impedimetric biosensor based on cell-mediated bioimprinted films for bacterial detection. *Biosens. Bioelectron.* **39**:282–288. <http://dx.doi.org/10.1016/j.bios.2012.07.078>.
 105. Wan Y, Zhang D, Wang Y, Hou B. 2010. A 3D-impedimetric immunosensor based on foam Ni for detection of sulfate-reducing bacteria. *Electrochem Commun.* **12**:288–291. <http://dx.doi.org/10.1016/j.elecom.2009.12.017>.
 106. La Belle JT, Shah M, Reed J, Nandakumar V, Alford TL, Wilson JW, Nickerson CA, Joshi L. 2009. Label-free and ultra-low level detection of *Salmonella enterica* serovar Typhimurium using electrochemical impedance spectroscopy. *Electroanalysis* **21**:2267–2271. <http://dx.doi.org/10.1002/elan.200904666>.
 107. Pournaras AV, Koraki T, Prodromidis MI. 2008. Development of an impedimetric immunosensor based on electropolymerized polytyramine films for the direct detection of *Salmonella typhimurium* in pure cultures of type strains and inoculated real samples. *Anal. Chim. Acta* **624**:301–307. <http://dx.doi.org/10.1016/j.aca.2008.06.043>.
 108. Zhu T, Pei ZH, Huang JY, Xiong CY, Shi SG, Fang J. 2010. Detection of bacterial cells by impedance spectra via fluidic electrodes in a microfluidic device. *Lab Chip* **10**:1557–1560. <http://dx.doi.org/10.1039/b925968f>.
 109. Luong JHT, Male KB, Glennon JD. 2008. Biosensor technology: technology push versus market pull. *Biotechnol. Adv.* **26**:492–500. <http://dx.doi.org/10.1016/j.biotechadv.2008.05.007>.
 110. Olivier GK, Cho A, Sanii B, Connolly MD, Tran H, Zuckermann RN. 2013. Antibody-mimetic peptoid nanosheets for molecular recognition. *ACS Nano* **7**:9276–9286. <http://dx.doi.org/10.1021/nn403899y>.
 111. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. 2012. scFv antibody: principles and clinical application. *Clin. Dev. Immunol.* **2012**:980250. <http://dx.doi.org/10.1155/2012/980250>.
 112. Muyldermans S. 2013. Nanobodies: natural single-domain antibodies. *Annu. Rev. Biochem.* **82**:775–797. <http://dx.doi.org/10.1146/annurev-biochem-063011-092449>.
 113. Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S. 2013. Nanobodies and their potential applications. *Nanomedicine* **8**:1013–1026. <http://dx.doi.org/10.2217/nmm.13.86>.
 114. Richman S, Kranz D, Stone J. 2009. Biosensor detection systems: engineering stable, high-affinity bioreceptors by yeast surface display. *Methods Mol. Biol.* **504**:323–350. http://dx.doi.org/10.1007/978-1-60327-569-9_19.
 115. Stumpp MT, Amstutz P. 2007. DARPin: a true alternative to antibodies. *Curr. Opin. Drug Disc.* **10**:153–159.
 116. Tiede C, Tang AAS, Deacon SE, Mandal U, Nettleship JE, Owen RL, George SE, Harrison DJ, Owens RJ, Tomlinson DC, McPherson MJ. 2014. Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications. *Protein Eng. Des. Sel.* **27**:145–155. <http://dx.doi.org/10.1093/protein/gzu007>.
 117. Leonard P, Hearty S, Brennan J, Dunne L, Quinn J, Chakraborty T, O’Kennedy R. 2003. Advances in biosensors for detection of pathogens in food and water. *Enzyme Microb. Technol.* **32**:3–13. [http://dx.doi.org/10.1016/S0141-0229\(02\)00232-6](http://dx.doi.org/10.1016/S0141-0229(02)00232-6).
 118. Gehring AG, Patterson DL, Tu SI. 1998. Use of a light-addressable potentiometric sensor for the detection of *Escherichia coli* O157:H7. *Anal. Biochem.* **258**:293–298. <http://dx.doi.org/10.1006/abio.1998.2597>.

Asif Ahmed received his B.Sc. (in biotechnology and genetic engineering) from Khulna University, Bangladesh, in 2002. He then completed his M.Sc. (in biomolecular sciences) at the Korea Institute of Science and Technology (KIST) in 2009 with a full scholarship. During his M.Sc. work, he designed drug candidates for the serotonin 2C receptor as antiobesity agents using molecular modeling tools. He is currently pursuing a Ph.D. in Professor Paul Millner’s lab with a research focus on nanofabrication of impedimetric immunosensors against pathogenic microorganisms. This year he was awarded “best final-year Ph.D. talk” in the Annual Postgraduate Symposium in the Faculty of Biological Sciences. He has already published several papers and coauthored a book on impedimetric biosensors for medical applications. Mr. Ahmed’s research interests cover molecular biotechnology and electrochemical biosensors for pathogen detection.



Jo V. Rushworth received her honors degree (B.Sc. in biochemistry with a research year studying microbiology in Paris and a National Gatsby Plant Science scholarship) and her Ph.D. (biochemistry/structural biology) from the University of Leeds, United Kingdom. During her Ph.D. work, she studied the molecular and structural biology of amyloid-beta oligomers, the causative agent of Alzheimer’s disease. One of her publications arising from this study was awarded “Best in JBC Neurobiology 2013.” Subsequently, Dr. Rushworth managed Professor Paul Millner’s group and developed impedimetric biosensors for specific detection of amyloid-beta oligomers. This line of research combines her interests in biomedical science and electrochemical diagnostics. Dr. Rushworth is currently a lecturer in the Faculty of Health and Life Sciences at De Montfort University, Leicester, United Kingdom, where she is setting up her own research group.



Continued next page

Natalie A. Hirst received a B.Sc. in experimental pathology in 2005, before receiving a medical degree in 2006 from the University of London, Barts and the London School of Medicine and Dentistry. She is a member of the Royal College of Surgeons of England, having passed the requisite examination. She is currently in her final year of study for a Ph.D. with the Bionanotechnology Group at the University of Leeds, having taken time out of full-time surgical training. Her current research is on the development of electrochemical biosensors for early detection of complications after bowel surgery.



Paul A. Millner received his B.Sc. in biochemistry and Ph.D. in plant science at the University of Leeds (United Kingdom) and then had post-doctoral fellowships at Purdue University (West Lafayette, IN, USA) and Imperial College (London, United Kingdom). He returned to Leeds in 1986 as a lecturer. After 15 years as a plant biotechnologist/protein chemist, Dr. Millner moved into the area of nano- and bionanotechnology, with a particular interest in the development of biosensors. Dr. Millner is currently the Head of the School of Biomedical Sciences at the University of Leeds and also leads the Bionanotechnology Group. Current programs in his group include work on electrochemical biosensors for diagnosis of STIs, MRSA, group A *Streptococcus*, and other bacteria, as well as biosensors for detecting bowel leakage after colorectal cancer resection. Dr. Millner's work is united by a deep interest in bioengineering on the nanoscale by interfacing biological reagents with surfaces to result in electrical communication or enhanced activity.

